Drug Type Monoclonal antibody |
Synonyms PD-L1 checkpoint inhibitor /ER-a36-inhibitor (Lee's Pharmaceutical/Shenogen Pharma Group) |
Target |
Action antagonists, inhibitors |
Mechanism ERα antagonists(Estrogen receptor alpha antagonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 20 Nov 2017 | |
| Neoplasms | Preclinical | China | 20 Nov 2017 |






